University of Utah Huntsman Cancer Institute, Salt Lake City, UT
Erin B. Bailey , Srinivas Kiran Tantravahi , Chesley E. Wells , Alli M. Straubhar , Julia A. Batten , Austin Poole , David D. Stenehjem , Neeraj Agarwal
Background: Thyroid dysfunction is a common adverse effect of VEGF TKIs. There are conflicting reports on survival benefit in association with hypothyroidism. Moreover, severity of hypothyroidism has not been correlated with survival outcomes in mRCC. Methods: From a single institutional database (2004-2013), we identified pts with mRCC receiving VEGF TKIs. Serial serum thyroid-stimulating hormone (TSH) values were collected, and at least two consecutive TSH values were required for inclusion. Progression free survival (PFS) and overall survival (OS) were assessed. Univariate and multivariate analyses were performed using the Kaplan-Meier method and COX Proportional Hazard models. Results: Of 125 pts treated with a VEGF TKI, 70 pts were eligible (median age 59 yrs, males 70%). The majority of pts had clear cell histology (74.3%) and were in the MSKCC (71.4%)and Heng (52.9%) intermediate-risk groups. Pts received the following TKIs: sunitinib (77.1%), sorafenib (12.9%), pazopanib (8.6%), and axitinib (1.4%). Thyroid dysfunction occurred in 45.7% of pts, of which 21.4% of pts had a TSH > 10 mIU/L during treatment. The median PFS and OS were significantly longer in pts with a TSH > 10 mIU/L compared with those with lower TSH values (Table). In the multivariate analysis, including age, sex, hand-foot syndrome (HFS), and risk criteria, a TSH > 10 mIU/L during TKI treatment remained significant for improvements in PFS and OS (PFS: HR 0.31, CI 0.11-0.73, p=0.0063; OS: HR 0.19, CI 0.04-0.58, p=0.0021). Conclusions: The severity of hypothyroidism (TSH > 10 mIU/L) directly correlates with improved survival outcomes in pts with mRCC treated with VEGF TKIs.
Thyroid status | n | PFS, months | OS, months |
---|---|---|---|
Euthyroid vs. TSH > ULN, but ≤ 10 mIU/L | 55 | 10.6 vs. 7.3 (HR 0.84, CI 0.44-1.65, p=0.5939) |
21.6 vs. 16.6 (HR 1.16, CI 0.56-2.59, p=0.6936) |
TSH > 10 mIU/L vs. TSH ≤ 10 mIU/L | 70 | 48.1 vs. 8.3 (HR 0.33, CI 0.12-0.72, p=0.0041) |
n/a vs. 21 (HR 0.22, CI 0.05-0.61, p=0.0020) |
Appreviations: ULN, upper limit of normal; n/a, not achieved.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Genitourinary Cancers Symposium
First Author: Neil J. Shah
2023 ASCO Genitourinary Cancers Symposium
First Author: Audreylie Lemelin
2014 ASCO Annual Meeting
First Author: Erin B. Bailey
2024 ASCO Genitourinary Cancers Symposium
First Author: Neil J. Shah